期刊
EXPERT REVIEW OF HEMATOLOGY
卷 7, 期 1, 页码 5-7出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/17474086.2014.870030
关键词
historical features; melphalan; multiple myeloma; novel agents; stem cell transplantation
类别
Effective therapy for multiple myeloma has existed for a little more than the last half century. The introduction of melphalan 55 years ago was followed by a stagnant period of four decades in which many combinations of alkylating agents and chemotherapeutic drugs were developed without a significant increase in overall survival. The first novel agent, thalidomide, was introduced 15 years ago when it was used as an anti-angiogenesis agent. This was followed by a proteasome inhibitor, bortezomib. Then lenalidomide, a second-generation analog of thalidomide was introduced. More recently carfilzomib, a proteasome inhibitor, and pomalidomide, a third-generation derivative of thalidomide have entered the marketplace. Many new agents are in development and potentially available for future therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据